当前位置: 首页 >> 检索结果
461. Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial.
作者: Vedat Hamuryudan.;Gulen Hatemi.;Koray Tascilar.;Necdet Sut.;Yilmaz Ozyazgan.;Emire Seyahi.;Cem Mat.;Sebahattin Yurdakul.;Hasan Yazici.
来源: Rheumatology (Oxford). 2010年49卷1期173-7页
To assess the influence of being free of major organ involvement during the early years of the disease on the prognosis of men with Behçet's syndrome (BS).
462. Maintenance of physical activity after Internet-based physical activity interventions in patients with rheumatoid arthritis.
作者: Emalie J Hurkmans.;Marleen H van den Berg.;Karel H Ronday.;Andreas J Peeters.;Saskia le Cessie.;Theodora P M Vliet Vlieland.
来源: Rheumatology (Oxford). 2010年49卷1期167-72页
To investigate the maintenance of physical activity 12 months after two 1-year Internet-based physical activity interventions in patients with RA.
463. A randomized comparative trial of generalized vs targeted physiotherapy in the management of childhood hypermobility.
作者: Sue Kemp.;Ian Roberts.;Carrol Gamble.;Stuart Wilkinson.;Joyce E Davidson.;Eileen M Baildam.;Andrew Gavin Cleary.;Liza J McCann.;Michael W Beresford.
来源: Rheumatology (Oxford). 2010年49卷2期315-25页
Joint hypermobility, common in childhood, can be associated with severe pain and significant morbidity. Physiotherapy, the mainstay of treatment, lacks a robust evidence base. This study is aimed at determining the best physiotherapy intervention in managing childhood hypermobility.
464. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.
作者: David Isenberg.;Gerald B Appel.;Gabriel Contreras.;Mary A Dooley.;Ellen M Ginzler.;David Jayne.;Jorge Sánchez-Guerrero.;David Wofsy.;Xueqing Yu.;Neil Solomons.
来源: Rheumatology (Oxford). 2010年49卷1期128-40页
To compare the efficacy and safety of mycophenolate mofetil (MMF) and intravenous cyclophosphamide (IVC) as induction treatment for lupus nephritis (LN), by race, ethnicity and geographical region.
465. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.
作者: Chris T Derk.;Elizabeth Grace.;Max Shenin.;Manisha Naik.;Steffan Schulz.;Wen Xiong.
来源: Rheumatology (Oxford). 2009年48卷12期1595-9页
To evaluate the efficacy and safety of mycophenolate mofetil for the treatment of SSc.
466. Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study.
作者: Dinesh Khanna.;Chi-Hong Tseng.;Daniel E Furst.;Philip J Clements.;Robert Elashoff.;Michael Roth.;David Elashoff.;Donald P Tashkin.; .
来源: Rheumatology (Oxford). 2009年48卷12期1537-40页
Scleroderma Lung Study (SLS) showed that cyclophosphamide (CYC) was better than placebo (PLA) in preventing progression of forced vital capacity percentage (FVC%) predicted and dyspnoea at 12 months. Our objective was to assess minimally important difference (MID) for Mahler's Transition Dyspnoea Index (TDI) in SLS.
467. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
作者: Martin Aringer.;Frederic Houssiau.;Caroline Gordon.;Winfried B Graninger.;Reinhard E Voll.;Eva Rath.;Guenter Steiner.;Josef S Smolen.
来源: Rheumatology (Oxford). 2009年48卷11期1451-4页
To follow-up on all available infliximab-treated SLE patients for safety and long-term efficacy in order to extract information that is useful for planning appropriate controlled trials with infliximab in SLE.
468. An analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographs.
作者: John D Carter.;Rajendra P Kedar.;Scott R Anderson.;Angie H Osorio.;Nancy L Albritton.;Shanmugapriya Gnanashanmugam.;Joanne Valeriano.;Frank B Vasey.;Louis R Ricca.
来源: Rheumatology (Oxford). 2009年48卷11期1442-6页
The aim of this study was to analyse the prevalence of occult destructive arthropathy in subjects with gout and normal plain radiographs by utilizing MRI and ultrasound (US).
469. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
作者: Martin Soubrier.;Xavier Puéchal.;Jean Sibilia.;Xavier Mariette.;Olivier Meyer.;Bernarde Combe.;René Marc Flipo.;Denis Mulleman.;Francis Berenbaum.;Charles Zarnitsky.;Thierry Schaeverbeke.;Patrice Fardellone.;Maxime Dougados.
来源: Rheumatology (Oxford). 2009年48卷11期1429-34页
In early and active RA despite MTX, continuous treatment with TNF blockers in combination with MTX is recommended. To compare this strategy with an initial combination of MTX and adalimumab (ADA) given for 3 months and then adjusted based on the disease activity status.
470. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis.
作者: Bernat Galarraga.;Faisel Khan.;Pradeep Kumar.;Tom Pullar.;Jill J F Belch.
来源: Rheumatology (Oxford). 2009年48卷11期1418-23页
Increased arterial stiffness, an independent risk factor for premature coronary artery disease, has been reported in patients with RA. The objectives of this study were first to assess, in patients with RA, the relationship between disease activity, inflammation and augmentation index, which is a combined measure of arterial stiffness and pulse wave reflection. The second objective was to establish any effect anti-rheumatic treatment may have on augmentation index.
471. Low-dose natural human interferon-alpha lozenges in the treatment of Behçet's syndrome.
作者: Hasan Kiliç.;Hasan E Zeytin.;Cengiz Korkmaz.;Cem Mat.;Ahmet Gül.;Fulya Coşan.;Ayhan Dinç.;Ismail Simşek.;Necdet Süt.;Hasan Yazici.
来源: Rheumatology (Oxford). 2009年48卷11期1388-91页
There had been evidence that low-dose local IFN could be beneficial in the management of recurrent oral ulcers (OUs). We investigated the efficacy and collected initial data on the safety of low-dose natural human IFN-alpha administered by the oral mucosal route in Behçet's syndrome (BS) in a placebo controlled, double blind study.
472. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.
作者: Kimme L Hyrich.;Chris Deighton.;Kath D Watson.; .;Deborah P M Symmons.;Mark Lunt.; .
来源: Rheumatology (Oxford). 2009年48卷10期1323-7页
Anti-TNF therapy has improved outcomes for patients with highly active RA. Less is known about its effectiveness in patients with lower disease activity. The aim of this analysis is to compare the response to anti-TNF therapy between RA patients with high (DAS28 > 5.1) and moderate (DAS28 > 3.2-5.1) disease activity.
473. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study.
作者: Aslam Anis.;Wei Zhang.;Paul Emery.;Huiying Sun.;Amitabh Singh.;Bruce Freundlich.;Reiko Sato.
来源: Rheumatology (Oxford). 2009年48卷10期1283-9页
To compare the impact of the combination of etanercept (ETN) and MTX with MTX alone on work productivity among MTX-naïve patients with active early RA over a 12-month period.
474. Usefulness of initial histological features for stratifying Sjogren's syndrome responders to mizoribine therapy.
作者: Shingo Nakayamada.;Takashi Fujimoto.;Akitaka Nonomura.;Kazuyoshi Saito.;Shinobu Nakamura.;Yoshiya Tanaka.
来源: Rheumatology (Oxford). 2009年48卷10期1279-82页
To evaluate the response of patients with SS to mizoribine therapy in relation to histological features of minor salivary glands.
475. Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?
作者: Lydia G Schipper.;Jaap Fransen.;Pilar Barrera.;Alfons A den Broeder.;Piet L C M Van Riel.
来源: Rheumatology (Oxford). 2009年48卷10期1247-53页
MTX, either alone or in combination with SSZ, is effective in the treatment of RA. Trials have shown that, after SSZ failure, the addition of MTX to SSZ is more effective than a switch to MTX. Whether this is also the case in daily practice has not been analysed yet. In this study, we compared the efficacy of a switch to MTX monotherapy with that of the addition of MTX to SSZ in the daily clinical practice of RA patients who had failed SSZ monotherapy in the Nijmegen RA Inception Cohort.
476. Improvements of muscle strength predicted benefits in HRQOL and postural balance in women with fibromyalgia: an 8-month randomized controlled trial.
作者: Pablo Tomas-Carus.;Narcis Gusi.;Arja Häkkinen.;Keijo Häkkinen.;Armando Raimundo.;Alfredo Ortega-Alonso.
来源: Rheumatology (Oxford). 2009年48卷9期1147-51页
To evaluate whether changes in muscle strength due to 32 weeks of supervised aquatic training predicted improvements on health-related quality of life (HRQOL).
477. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials.
作者: Marian Kaldas.;Puja P Khanna.;Daniel E Furst.;Philip J Clements.;Weng Kee Wong.;James R Seibold.;Arnold E Postlethwaite.;Dinesh Khanna.; .
来源: Rheumatology (Oxford). 2009年48卷9期1143-6页
The modified Rodnan skin score (MRSS) is a standard outcome measure for skin disease in SSc and calculated by summation of skin thickness in 17 different body sites (total score = 51). Our objective was to evaluate the sensitivity of change over time of individual body sites used in the calculation of total MRSS.
478. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.
作者: Nathan Vastesaeger.;Stephen Xu.;Daniel Aletaha.;E William St Clair.;Josef S Smolen.
来源: Rheumatology (Oxford). 2009年48卷9期1114-21页
Identifying patients with RA at high risk of rapid radiographic progression (RRP) is critical for making appropriate treatment decisions. We developed an exploratory prediction model for the risk of RRP using an RA study population undergoing either conservative or aggressive disease management.
479. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
作者: Gerd Horneff.;Annette Ebert.;Sigrid Fitter.;Kirsten Minden.;Ivan Foeldvari.;Jasmin Kümmerle-Deschner.;Angelika Thon.;Herrmann J Girschick.;Frank Weller.;Hans I Huppertz.
来源: Rheumatology (Oxford). 2009年48卷8期916-9页
Etanercept, a recombinant TNF receptor fusion protein, has been approved for the treatment of resistant polyarticular course juvenile idiopathic arthritis at a dosage of 0.4 mg/kg twice weekly in children older than 4 years. In adult patients, efficacy and safety of etanercept 25 mg twice weekly was comparable with 50 mg once weekly. Therefore, safety and efficacy of etanercept once weekly 0.8 mg/kg up to 50 mg s.c. was evaluated in a 3 month open label trial.
480. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
作者: Edmund K Li.;Lai-Shan Tam.;Tracy Y Zhu.;Martin Li.;Catherine L Kwok.;Tena K Li.;Ying Ying Leung.;Kong Chiu Wong.;Cheuk Chun Szeto.
来源: Rheumatology (Oxford). 2009年48卷8期892-8页
To assess if combination rituximab and cyclophosphamide is more effective than rituximab monotherapy as an induction therapy for proliferative lupus nephritis.
|